¥287.30   ( %)
前日收盘: 当日成交量(股): 当日最高: 总股本:1425.07万
当日开盘: 当日成交额(元): 当日最低: 流通股本:
市盈率(动/静):0/0 市净率:0 市销率:0 总市值:40.94亿
52周最高:325.98 52周最低:15.15 转让方式: 单位:美元
$Madrigal Pharmaceuticals(MDGL)$
  • 还可以输入
  • 20016

Madrigal Pharmaceuticals(MDGL) 06月23日 07时09分

查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 09时24分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:BATE KENNETH
公告日:2018-06-21, 内部交易人:BATE KENNETH, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008929, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008929/0001179110-18-008929-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时32分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Levy Richard S
公告日:2018-06-21, 内部交易人:Levy Richard S, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008928, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008928/0001179110-18-008928-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时31分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:MILLIGAN DAVID V
公告日:2018-06-21, 内部交易人:MILLIGAN DAVID V, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008927, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008927/0001179110-18-008927-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时31分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Gollust Keith R
公告日:2018-06-21, 内部交易人:Gollust Keith R, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008926, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008926/0001179110-18-008926-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时31分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:CRAVES FRED B
公告日:2018-06-21, 内部交易人:CRAVES FRED B, 与发行人关系:/董事/10%持股人/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008925, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008925/0001179110-18-008925-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月14日 06时43分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Schneebaum Marc R
公告日:2018-06-13, 内部交易人:Schneebaum Marc R, 与发行人关系:Chief Financial Officer/高管/, 操作:卖出,10099(股)Common Stock,均价$287.4600; 操作码:M,5223(股)Common Stock; 操作码:M,2734(股)Common Stock; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008437, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008437/0001179110-18-008437-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:CRAVES FRED B
公告日:2018-06-12, 内部交易人:CRAVES FRED B, 与发行人关系:/董事/10%持股人/, 操作:卖出,280000(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008430, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008430/0001179110-18-008430-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:FRIEDMAN PAUL A
公告日:2018-06-12, 内部交易人:FRIEDMAN PAUL A, 与发行人关系:Chief Executive Officer/董事/高管/, 操作:卖出,73526(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008428, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008428/0001179110-18-008428-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Taub Rebecca
公告日:2018-06-12, 内部交易人:Taub Rebecca, 与发行人关系:Chief Medical Officer, EVP R&D/董事/高管/, 操作:卖出,73526(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008426, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008426/0001179110-18-008426-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:BAY CITY CAPITAL LLC
公告日:2018-06-12, 内部交易人:BAY CITY CAPITAL LLC, 与发行人关系:/董事/10%持股人/, 操作:卖出,280000(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008424, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008424/0001179110-18-008424-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月10日 14时31分

新闻 Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: ......  url.vc.watch/giJx
查看全文

Madrigal Pharmaceuticals(MDGL) 06月10日 14时31分

新闻 Madrigal Pharmaceuticals Prices Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a cli ......  url.vc.watch/giJ9
查看全文

Madrigal Pharmaceuticals(MDGL) 06月09日 11时15分

查看全文

Madrigal Pharmaceuticals(MDGL) 06月08日 04时38分

查看全文

Madrigal Pharmaceuticals(MDGL) 06月06日 18时39分

查看全文

Madrigal Pharmaceuticals(MDGL) 06月06日 07时17分

查看全文

Madrigal Pharmaceuticals(MDGL) 06月04日 17时38分

新闻 Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial Madrigal's MGL-3196 Achiev ......  url.vc.watch/gCwu
查看全文

Madrigal Pharmaceuticals(MDGL) 06月02日 05时40分

新闻 BUZZ-Street View: Madrigal Pharma deal-ready after strong NASH drug data
** Madrigal Pharmaceuticals Inc's (MDGL.O) oral drug for fatty liver disease NASH - which has no ......  url.vc.watch/gGsY
查看全文

Madrigal Pharmaceuticals(MDGL) 05月31日 21时29分

查看全文
  • 首页 上一页 1 2 3 下一页 尾页  每页20条/共49